These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15716585)

  • 1. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.
    Crooke RM; Graham MJ; Lemonidis KM; Whipple CP; Koo S; Perera RJ
    J Lipid Res; 2005 May; 46(5):872-84. PubMed ID: 15716585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.
    Mullick AE; Fu W; Graham MJ; Lee RG; Witchell D; Bell TA; Whipple CP; Crooke RM
    J Lipid Res; 2011 May; 52(5):885-96. PubMed ID: 21343632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization.
    Alger HM; Brown JM; Sawyer JK; Kelley KL; Shah R; Wilson MD; Willingham MC; Rudel LL
    J Biol Chem; 2010 May; 285(19):14267-74. PubMed ID: 20231283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the expression of genes encoding apolipoproteins B100 and B48 and the low density lipoprotein receptor in nonhuman primates. Comparison of dietary fat and cholesterol.
    Sorci-Thomas M; Wilson MD; Johnson FL; Williams DL; Rudel LL
    J Biol Chem; 1989 May; 264(15):9039-45. PubMed ID: 2722816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.
    Lee RG; Fu W; Graham MJ; Mullick AE; Sipe D; Gattis D; Bell TA; Booten S; Crooke RM
    J Lipid Res; 2013 Mar; 54(3):602-614. PubMed ID: 23220583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
    Bell DA; Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
    Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
    Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of the apolipoprotein E by dietary lipids occurs by transcriptional and post-transcriptional mechanisms.
    Srivastava RA
    Mol Cell Biochem; 1996 Feb; 155(2):153-62. PubMed ID: 8700160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
    Reyes-Soffer G; Moon B; Hernandez-Ono A; Dionizovik-Dimanovski M; Jimenez J; Obunike J; Thomas T; Ngai C; Fontanez N; Donovan DS; Karmally W; Holleran S; Ramakrishnan R; Mittleman RS; Ginsberg HN
    Sci Transl Med; 2016 Jan; 8(323):323ra12. PubMed ID: 26819195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dietary fats and cholesterol on liver lipid content and hepatic apolipoprotein A-I, B, and E and LDL receptor mRNA levels in cebus monkeys.
    Hennessy LK; Osada J; Ordovas JM; Nicolosi RJ; Stucchi AF; Brousseau ME; Schaefer EJ
    J Lipid Res; 1992 Mar; 33(3):351-60. PubMed ID: 1314879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
    Fu T; Mukhopadhyay D; Davidson NO; Borensztajn J
    J Biol Chem; 2004 Jul; 279(27):28662-9. PubMed ID: 15123680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia.
    Thomas T; Ginsberg H
    Curr Atheroscler Rep; 2010 Jan; 12(1):58-65. PubMed ID: 20425272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo regulation of low-density lipoprotein receptor and apolipoprotein B gene expressions by dietary fat and cholesterol in inbred strains of mice.
    Srivastava RA; Jiao S; Tang JJ; Pfleger BA; Kitchens RT; Schonfeld G
    Biochim Biophys Acta; 1991 Oct; 1086(1):29-43. PubMed ID: 1683257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids.
    Tadin-Strapps M; Peterson LB; Cumiskey AM; Rosa RL; Mendoza VH; Castro-Perez J; Puig O; Zhang L; Strapps WR; Yendluri S; Andrews L; Pickering V; Rice J; Luo L; Chen Z; Tep S; Ason B; Somers EP; Sachs AB; Bartz SR; Tian J; Chin J; Hubbard BK; Wong KK; Mitnaul LJ
    J Lipid Res; 2011 Jun; 52(6):1084-1097. PubMed ID: 21398511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.
    Kastelein JJ; Wedel MK; Baker BF; Su J; Bradley JD; Yu RZ; Chuang E; Graham MJ; Crooke RM
    Circulation; 2006 Oct; 114(16):1729-35. PubMed ID: 17030687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic mice expressing full-length human apolipoprotein B-100. Full-length human apolipoprotein B mRNA is essentially not edited in mouse intestine or liver.
    Xiong W; Zsigmond E; Gotto AM; Reneker LW; Chan L
    J Biol Chem; 1992 Oct; 267(30):21412-20. PubMed ID: 1400454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor-knockout mice by adenovirus-mediated gene delivery of ApoB mRNA editing enzyme (Apobec1).
    Teng B; Ishida B; Forte TM; Blumenthal S; Song LZ; Gotto AM; Chan L
    Arterioscler Thromb Vasc Biol; 1997 May; 17(5):889-97. PubMed ID: 9157952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms.
    Srivastava RA; Averna M; Srivastava N; Pape ME
    Int J Biochem Cell Biol; 2001 Dec; 33(12):1215-26. PubMed ID: 11606258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic lipase overexpression lowers remnant and LDL levels by a noncatalytic mechanism in LDL receptor-deficient mice.
    Dichek HL; Johnson SM; Akeefe H; Lo GT; Sage E; Yap CE; Mahley RW
    J Lipid Res; 2001 Feb; 42(2):201-10. PubMed ID: 11181749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.